Author(s):
Akshata Mahendrasing Girase, Amitkumar R. Dhankani, Mansi A. Dhankani, Sunil P. Pawar
Email(s):
akshatagirase1510@gmail.com
DOI:
10.52711/2231-5675.2025.00019 
Address:
Akshata Mahendrasing Girase, Amitkumar R. Dhankani, Mansi A. Dhankani, Sunil P. Pawar
P.S.G.V.P Mandal’s College of Pharmacy, Shahada, Dist- Nandurbar, Maharashatra –India Postal Code -425409.
*Corresponding Author
Published In:
Volume - 15,
Issue - 2,
Year - 2025
ABSTRACT:
Selexipag (SLP), a pyrazine derivative with the molecular formula C26H32N4O4S, is an oral selective prostacyclin receptor (IP receptor) agonist approved by the U.S. Food and Drug Administration (FDA) in 2015 for the treatment of pulmonary arterial hypertension (PAH) in patients classified under functional class II or III. Its active metabolite, ACT-333679, exhibits approximately 130-fold selectivity towards the IP receptor, contributing to its potent vasodilatory, anti-proliferative, anti-inflammatory, and anti-thrombotic effects. Selexipag is rapidly absorbed, undergoing hepatic metabolism via carboxylesterase 1 and subsequent oxidative metabolism through CYP3A4 and CYP2C8 enzymes. The drug demonstrates a terminal half-life of 0.8 to 2.5 hours, while its active metabolite has a prolonged half-life of 6.2 to 13.5 hours. Analytical techniques for the quantification of Selexipag in bulk and pharmaceutical formulations include high-performance liquid chromatography (HPLC), LC-MS/MS, and UV-visible spectrophotometry. This study focuses on the development and validation of a rapid, precise, and accurate HPLC method for Selexipag analysis in accordance with ICH (Q2) R1 guidelines. The method was optimized for linearity, accuracy, precision, robustness, and specificity. The proposed method demonstrated excellent reproducibility and stability, making it suitable for routine quality control analysis and pharmacokinetic studies. This work aims to enhance the analytical reliability of Selexipag and contribute to improved therapeutic monitoring and patient outcomes in the management of PAH
Cite this article:
Akshata Mahendrasing Girase, Amitkumar R. Dhankani, Mansi A. Dhankani, Sunil P. Pawar. A Critical Review on Selexipag: From Molecular Mechanism to Analytical Method Development. Asian Journal of Pharmaceutical Analysis. 2025; 15(2):116-2. doi: 10.52711/2231-5675.2025.00019
Cite(Electronic):
Akshata Mahendrasing Girase, Amitkumar R. Dhankani, Mansi A. Dhankani, Sunil P. Pawar. A Critical Review on Selexipag: From Molecular Mechanism to Analytical Method Development. Asian Journal of Pharmaceutical Analysis. 2025; 15(2):116-2. doi: 10.52711/2231-5675.2025.00019 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2025-15-2-8
REFERENCE:
1. Scott LJJD. Selexipag: first global approval. Drugs. 2016; 76: 413-8. https://doi.org/10.1007/s40265-016- 0549-4
2. Xie S, Shi L, Chen J, Xu R, Ye X. Analysis B, Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method. J Pharm Biomed Anal. 2020; 190:113496. https://doi.org/10.1016/j.jpba.2020.113496
3. Damireddy S, Pravalika K, Praveen M, Sathish G, Anusha M. Method development and validation of selexipag in its bulk and dosage form by rp-HPLC. J Int J Pharm Biol Sci. 2017; 7:84. ISSN: 2230-7605
4. Youssef YM, Mahrouse MA, Mostafa E. Assessment of environmental impact of a novel stabilityindicating RP-HPLC method and reported methods for the determination of selexipag in bulk and dosage form: A comparative study using different greenness assessment tools. Microchem J. 2023; 185:108256. https://doi.org/10.1016/j.microc.2022.108256
5. Amara Babu NL, Koganti K, Palakeeti B, Srinivas KS, Rao KP. Development of an efficient stability-indicating LC–MS/MS method for the analysis of selexipag and characterization of its degradation products. Biomed. Chromatogr. 2021; 35(10): e5178.
6. Gorumutchu GP, Ratnakaram NR. Oxidative coupling: A tranquil approach for determination of selexipag by visible spectrophotometry. Orient. J. Chem. 2018; 34(6): 3112. http://dx.doi.org/10.13005/ojc/340656
7. Prathyusha SM, Deepti CA, Naik RR, Technology. Development and validated of spectrophotometric methods for the determination of Selexipag (An antihypertensive agent). RJPT. 2020;13(3):1346-50. https://doi.org/10.5958/0974-360X.2020.00248.6
8. Sharma K: Selexipag for the treatment of pulmonary arterial hypertension. Expert Rev Respir Med. 2016 Jan; 10(1): 1-3. doi: 10.1586/17476348.2016.1121103. Epub 2015 Dec 7.
9. Kaufmann P, Okubo K, Bruderer S, Mant T, Yamada T, Dingemanse J, Mukai H: Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag. Am J Cardiovasc Drugs. 2015 Jun; 15(3): 195-203. doi: 10.1007/s40256-015-0117-4.
10. Kaufmann P, Okubo K, Bruderer S, et al. Pharmacokinetics and toler ability of the novel oral prostacyclin IP receptor agonist selexipag. Am J Cardiovasc Drugs. 2015;15(3):195–203.
11. U.S Department of Health and Human Services, Food and Drug Admin istration. US Prescribing Information: Uptravi (Selexipag) Tables, for Oral Use; 2015; 2016. Available from: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2015/207947s000lbl.pdf. Accessed September 25, 2016.
12. Kuwano K, Hashino A, Noda K, Kosugi K, Kuwabara K. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6 diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetam ide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl) (isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther. 2008; 326(3): 691–699
13. Xie S, Shi L, Chen J, Xu R-a, Ye X. Simultaneous quantification and pharmacokinetic investigation of Selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method. J Pharm Biomed Anal. 2020; 190:113496. DOI: 10.1016/j.jpba.2020.113496
14. Bruderer S, Okubo K, Mukai H, Mant T, Dingemanse J. Investigation of potential pharmacodynamic and pharmacokinetic interactions between Selexipag and warfarin in healthy male subjects. ClinTher. 2016; 38(5): 1228–1236. DOI: 10.1016/j.clinthera.2016.03.014
15. Gnerre C, Segrestaa J, Seeland S, et al. The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist Selexipag. Xenobiotica. 2018; 48(7): 704–719. DOI: 10.1080/00498254.2017.1357088
16. Chauhan A, Mittu B, Chauhan P. Analytical method development and validation: a concise review. J Anal Bioanal Tech. 2015; 6(1): 1-5.
17. Pravallika, K. E.; Ravi, P.; Abboodi, A. H.; Razzaq, A. H.; Sasivardhan, O. Development and Validation of UV Spectrophotometric Methods for the Estimation of Vortioxetine Hydrobromide in Bulk and Pharmaceutical Dosage Forms. Rese. Jour. of Pharm. and Technol. 2017; 10(11): 3928. https://doi.org/10.5958/0974–360X.2017.00713.2
18. J L Aldabib, M F Edbeib. The Effects of Concentration based on the absorbance form the Ultraviolet Visible Spectroscopy. International Journal of Science Letters. 2020; 2(1): 1-11
19. NamrathaSunkara, B. Manisha, B. Harshita, B. Anjali, B. Ishwarya, B. Akhila Gas chromatography. World Journal of Pharmaceutical Science and Research. 2024;3(1): 23-26
20. MacNair JE, Lewis KC, Jorgenson JW. Ultrahigh-pressure reversed-phase liquid chromatography in packed capillary columns. Anal Chem. 1997; 69(6):983-989.
21. Walter TH, Andrews RW. Recent innovations in UHPLC columns and instrumentation. TrAC Trends Anal Chem. 2014; 63:14-20
22. Snyder, L.R., J.J. Kirkland and J.L. Glajch, 1997. Practical HPLC Method Development, 2 Edition, Wiley-Interscience, New York, pp: 41-43.
23. Attimarad M, Ahmed KK, Aldhubaib BE, Harsha S. High-performance thin layer chromatography: A powerful analytical technique in pharmaceutical drug discovery. Pharm Methods. 2011 Apr; 2(2): 71-5. Doi: 10.4103/2229-4708.84436.
24. Kaushal C, Srivastava B. A Process of Method Development: A Chromatographic Approach. J Chem Pharm Res, 2010; 2(2): 519-545.
25. Borade S and Charushila JB: Validation and forced degradation by RP-HPLC of selexipag drug in bulk and dosage form. Int J Pharm Sci& Res 2024; 15(8): 2517-22. doi: 10.13040/IJPSR.0975-8232.15(8).2517-22
26. Saniye Ozcan, Egemen Guvenç Ogut, Serkan Levent, Nafiz Oncu can. A new HPLC method for selexipag analysis in pharmaceutical formulation and bulk form. European Journal of Life Sciences. 2023; 2; 53-58.
27. BurhanCeylan, GizemTırıs, S. EvrimKepekciTekkeli, CemÖnal and ArmaganÖnal; A novel HPLC method for selexipag in human plasma and application to a prototype pharmacokinetic study; Ak journals; vol 36 , November 23, 2023; 273–278
28. Santosh SS and Devi NK. Stability Indicating Method Development and Validation of Selexipag in Bulk and Pharmaceutical Dosage form by using RP-HPLC. Pharm Res 2021, 5(2): 000239.
29. Koya Prabhakara Rao, Namburi LA Amara babu, Kalyani Koganti, Babji Palakeeti, Koduri S. V. Srinivas. Related substances method development and validation of an LCMS/ MS method for quantifcation of selexipag and its related impurities in rat plasma and its application to pharmacokinetic studies. SN Applied Sciences. 2021
30. Banothu Bhadru, V. Venkata Rao, Suryadevara Vidhyadhara. Development and Validation of Bioanalytical Method for the Quantitative Estimation of Selexipag In Biological Matrices using LC-MS/ MS. J. Pharm. Sci. & Res. Vol. 11(7), 2019, 2722-2727.
31. KotwalTanuja Suresh et al. Development and Validation of Simple Uv Spectrophotometric Method for the Determination of Selexipag in API and its Bulk Dosage Form. Indo American Journal of Pharmaceutical Research. 2017: 7(5).
32. Snigdha Damireddy, K. Pravalika, M. Praveen, G. Sathish, M. Anusha. Method development and validation of Selexipag in its bulk and dosage form by RP-HPLC. International Journal of Pharmacy and Biological Sciences. 2017; 7(4): 84-92.
33. Priska Kaufmann, Kaori Okubo, ShirinBruderer, TimMant, Tetsuhiro Yamada, Jasper Dingemanse, Hideya Mukai; Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor AgonistSelexipag. Am J Cardiovasc Drugs. 2015; 15: 195–203.